Superior efficacy of VTD over VCD as induction therapy for autotransplantation-eligible, newly diagnosed, myeloma patients

Cavo M., Pantani L., Pezzi A., Cavallo F., Petrucci M.T., Di Raimondo F., Patriarca F., Waage A., Zamagni E., Montefusco V., Galli M., Gamberi B., Rossi G., Tacchetti P., Grasso M., Zweegman S., Offidani M., Ballanti S., Zambello R., Liberati A.M.Bassan R., Pregno P., Palumbo A., Sonneveld P.

Research output: Contribution to journalArticleAcademicpeer-review


Introduction Three-drug induction regimens including a first or second generation proteasome inhibitor are a current standard of care for autologous stem-cell transplantation (ASCT)-eligible, newly diagnosed, multiple myeloma (MM) patients (pts). In the absence of prospective randomized studies comparing different induction regimens, it is difficult to recommend one treatment over another, and the choice is ultimately based upon physician's preference or single center's policy. Bortezomib-thalidomide-dexamethasone (VTD) has been recently approved by EMA as induction for previously untreated, ASCT-eligible, MM pts. Bortezomib combined with cyclophosphamide and dexamethasone (VCD) is an attractive alternative to VTD, although efficacy results have not been backed by phase III studies. The present study aimed to evaluate the differences in response rates and toxicity between VTD and VCD induction regimens in preparation for subsequent ASCT. Methods Two hundred and thirty six pts who were randomized to the VTD arm of the GIMEMA-MMY-3006 study were compared with an equal number of pair mates who received induction therapy with VCD as part of the EMN02 trial designed to prospectively compare ASCT up front vs bortezomib-melphalan-prednisone followed by ASCT at the time of relapse or progression. Both groups of pts were treated in Italian centers participating in the two phase III studies. Case matching was performed with respect to the following pt characteristics at baseline: age (± 2 years), ISS stage (1 vs 2 vs 3), t(4;14) (detected by FISH in ≥ 10% vs <10% CD138+ bone marrow plasma cells) and del(17p) (≥ 20% vs
Original languageEnglish
Issue number21
Publication statusPublished - 2014

Cite this